Abstract

Simple SummaryIn this study, the effect of vitamin D supplementation on pain, infections, fatigue and quality of life in patients with advanced cancer with verified vitamin D deficiency was studied. To this end, a randomized controlled trial, ‘Palliative-D’, was conducted, comparing the effect of 4000 IU vitamin D3/day for 12 weeks to placebo in cancer patients admitted to palliative care. Pain was assessed as change in opioid dose and infections measured as days on antibiotics. Vitamin D-supplemented patients increased their opioid doses at a significantly slower rate than patients receiving placebo, i.e., 0.56 µg less fentanyl/h per week with vitamin D treatment. Vitamin D reduced self-assessed fatigue but did not affect antibiotic use or self-assessed Quality of life. The treatment was safe and well-tolerated. In conclusion, correction of vitamin D deficiency may have positive effects on pain and fatigue in palliative cancer patients.The aim of the ‘Palliative-D’ study was to test the hypothesis that correction of vitamin D deficiency reduces opioid use in cancer patients admitted to palliative care. A multicenter randomized, placebo-controlled, double-blind trial in three home-based palliative care facilities in Sweden was performed. Patients with advanced cancer and 25-hydroxyvitamin D < 50 nmol/L were randomized to vitamin D3 4000 IU/day or placebo for 12 weeks. The primary endpoint was the difference of long-acting opioid use (fentanyl ug/h) between the groups during 12 weeks, based on four time points. Secondary outcomes included changes in antibiotic use, fatigue and Quality of Life (QoL). A total of 244 patients were randomized, and 150 patients completed the 12 weeks. The major reason for drop-out was death due to cancer. The vitamin D-group had a significantly smaller increase of opioid doses compared to the placebo-group; beta coefficient −0.56 (p = 0.03), i.e., 0.56 µg less fentanyl/h per week with vitamin D treatment. Vitamin D-reduced fatigue assessed with ESAS was −1.1 points after 12 weeks (p < 0.01). Antibiotic use or QoL did not differ significantly between the groups. The treatment was safe and well-tolerated. In conclusion, correction of vitamin D deficiency may have positive effects on opioid use and fatigue in palliative cancer patients, but only in those with a survival time more than 12 weeks.

Highlights

  • Vitamin D is a steroid hormone that maintains calcium homeostasis and skeletal health [1]

  • Patients were withdrawn from the study if they developed hypercalcemia, if eGFR dropped below 30 mL/min, if they were prescribed medications that were not allowed according to the study protocol, had poor compliance, could no longer take the study drug, withdrew consent, were lost to follow-up or reported serious or intolerable adverse events

  • The vitamin D group exhibited a significantly lower degree of fatigue assessed with Edmonton Symptom Assessment Scale (ESAS) compared to the placebo group after 12 weeks; −1.1 point (p < 0.01) (Figure 3)

Read more

Summary

Introduction

Vitamin D is a steroid hormone that maintains calcium homeostasis and skeletal health [1]. Vitamin D reduces cytokine release, dampens inflammatory T-cell responses and has been shown to downregulate prostaglandin synthesis [6,7,8,9] These findings provide a possible mechanistic explanation for effects of vitamin D supplementation regarding infections and pain. A cross-sectional observational study at our palliative care facility revealed that lower levels of 25-OHD were associated with prescription of higher doses of opioids [17]. Based on this observation, we performed a pilot study, where 39 patients with vitamin D deficiency were supplemented with vitamin D3 oil drops (4000 IU/day) for 12 weeks [23]. To test whether these results could be reproduced in a randomized and placebo-controlled setting, we designed the ‘PalliativeD’ study

Study Design
Participants
Randomization and Masking
Interventions
Outcomes
Monitoring of Adverse Events
Sample Size
Statistical Analyses
Results
Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call